Medical Imaging Specialist Guerbet Celebrates Its 90th Year
By Sanjit Dutt Posted on 15 Nov 2016 |
Guerbet (Paris, France), a specialist in contrast agents and solutions for medical imaging, will be celebrating its 90th year on November 15, 2016. The Group is one of the leading players in medical imaging worldwide and offers a full range of medical solutions and services.
The company is named after the French chemist Marcel Guerbet who discovered the world’s first iodinated contrast agent Lipidol, in 1901. His son André Guerbert, founded the company on November 15, 1926. Following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago, Guerbet has grown from being an essentially France-focused company to an international group. Today, 83% of Guerbet’s sales are generated outside France, driven by its four growth engines: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
Guerbet announced the celebration of its 90th anniversary at the French Radiology Congress, which was held in Paris from October 14 to 17, where a fresco featuring the outstanding dates in the company’s history was unveiled in the presence of the President of the French Radiology Society. Over the coming months, Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences in line with its celebration of “90 years of passion.” Guerbet’s website also features a video illustrating 90 years of the company’s history.
Yves L’Epine, Guerbet CEO, said, “Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.” He added, “More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”
Related Links:
Guerbet
The company is named after the French chemist Marcel Guerbet who discovered the world’s first iodinated contrast agent Lipidol, in 1901. His son André Guerbert, founded the company on November 15, 1926. Following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago, Guerbet has grown from being an essentially France-focused company to an international group. Today, 83% of Guerbet’s sales are generated outside France, driven by its four growth engines: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
Guerbet announced the celebration of its 90th anniversary at the French Radiology Congress, which was held in Paris from October 14 to 17, where a fresco featuring the outstanding dates in the company’s history was unveiled in the presence of the President of the French Radiology Society. Over the coming months, Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences in line with its celebration of “90 years of passion.” Guerbet’s website also features a video illustrating 90 years of the company’s history.
Yves L’Epine, Guerbet CEO, said, “Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.” He added, “More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”
Related Links:
Guerbet
Latest Industry News News
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
- Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions
- Polish Med-Tech Company BrainScan to Expand Extensively into Foreign Markets
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Channels
Radiography
view channel
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read more
AI-Powered Imaging Technique Shows Promise in Evaluating Patients for PCI
Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a minimally invasive procedure where small metal tubes called stents are inserted into partially blocked coronary arteries... Read moreMRI
view channel
AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more
Ultra-Powerful MRI Scans Enable Life-Changing Surgery in Treatment-Resistant Epileptic Patients
Approximately 360,000 individuals in the UK suffer from focal epilepsy, a condition in which seizures spread from one part of the brain. Around a third of these patients experience persistent seizures... Read more
AI-Powered MRI Technology Improves Parkinson’s Diagnoses
Current research shows that the accuracy of diagnosing Parkinson’s disease typically ranges from 55% to 78% within the first five years of assessment. This is partly due to the similarities shared by Parkinson’s... Read more
Biparametric MRI Combined with AI Enhances Detection of Clinically Significant Prostate Cancer
Artificial intelligence (AI) technologies are transforming the way medical images are analyzed, offering unprecedented capabilities in quantitatively extracting features that go beyond traditional visual... Read moreUltrasound
view channel.jpeg)
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read more
AI Identifies Heart Valve Disease from Common Imaging Test
Tricuspid regurgitation is a condition where the heart's tricuspid valve does not close completely during contraction, leading to backward blood flow, which can result in heart failure. A new artificial... Read moreNuclear Medicine
view channel
Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
COX-2, an enzyme that plays a key role in brain inflammation, can be significantly upregulated by inflammatory stimuli and neuroexcitation. Researchers suggest that COX-2 density in the brain could serve... Read more
Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which represents 15-20% of all breast cancer cases, is one of the most aggressive subtypes, with a five-year survival rate of about 40%. Due to its significant heterogeneity... Read moreGeneral/Advanced Imaging
view channel
AI-Powered Imaging System Improves Lung Cancer Diagnosis
Given the need to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules. However, obtaining tissue samples... Read more
AI Model Significantly Enhances Low-Dose CT Capabilities
Lung cancer remains one of the most challenging diseases, making early diagnosis vital for effective treatment. Fortunately, advancements in artificial intelligence (AI) are revolutionizing lung cancer... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more